Target Patient Population: Hypertension patients who are on an SGLT2 or will benefit from the addition of an SGLT2.
Study Overview: Will determine whether baxdrostat/ dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR
Study Timeline: Anticipated patient participation is 28 Months, 15 visits to the clinic
Number of Patients Currently Active in the Trial: 2
